BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
US Department of Justice
Federal Trade Commission
Mallinckrodt
Argus Health
AstraZeneca
Julphar
Chinese Patent Office
McKesson
Medtronic

Generated: January 18, 2018

DrugPatentWatch Database Preview

Luitpold Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for LUITPOLD PHARMS INC, and what generic alternatives to LUITPOLD PHARMS INC drugs are available?

LUITPOLD PHARMS INC has fifteen approved drugs.

There are four US patents protecting LUITPOLD PHARMS INC drugs.

There are fifty-six patent family members on LUITPOLD PHARMS INC drugs in thirty countries and sixteen supplementary protection certificates in eight countries.

Summary for Luitpold Pharms Inc
International Patents:56
US Patents:4
Tradenames:15
Ingredients:15
NDAs:15

Drugs and US Patents for Luitpold Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Luitpold Pharms Inc TESTOSTERONE CYPIONATE testosterone cypionate INJECTABLE;INJECTION 207742-001 Jun 16, 2017 AO RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Luitpold Pharms Inc OXALIPLATIN oxaliplatin INJECTABLE;IV (INFUSION) 204378-001 May 12, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Luitpold Pharms Inc INJECTAFER ferric carboxymaltose INJECTABLE;INTRAVENOUS 203565-001 Jul 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Luitpold Pharms Inc DACTINOMYCIN dactinomycin INJECTABLE;INJECTION 202562-001 Aug 23, 2013 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Luitpold Pharms Inc INJECTAFER ferric carboxymaltose INJECTABLE;INTRAVENOUS 203565-001 Jul 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Luitpold Pharms Inc OXALIPLATIN oxaliplatin INJECTABLE;IV (INFUSION) 204378-002 May 12, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Luitpold Pharms Inc INJECTAFER ferric carboxymaltose INJECTABLE;INTRAVENOUS 203565-001 Jul 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Luitpold Pharms Inc DEXMEDETOMIDINE HYDROCHLORIDE dexmedetomidine hydrochloride INJECTABLE;INJECTION 203773-001 May 12, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Luitpold Pharms Inc BUSULFAN busulfan INJECTABLE;INJECTION 202259-001 Dec 22, 2015 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Luitpold Pharms Inc INJECTAFER ferric carboxymaltose INJECTABLE;INTRAVENOUS 203565-001 Jul 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Luitpold Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,431,549 Methods and compositions for administration of iron ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Luitpold Pharms Inc Drugs

Supplementary Protection Certificates for Luitpold Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
02/028 Ireland ➤ Subscribe PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
C/GB03/033 United Kingdom ➤ Subscribe PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
C/GB95/031 United Kingdom ➤ Subscribe PRODUCT NAME: GEMCITABINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY- ACCEPTABLE SALT; REGISTERED: NL RVG17854 19950327; UK 00006/0301 19951026; UK 00006/0302 19951026
00117 Netherlands ➤ Subscribe PRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830
/1997 Austria ➤ Subscribe PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
00125 Netherlands ➤ Subscribe PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
2008006,C0933372 Lithuania ➤ Subscribe PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
C/GB08/018 United Kingdom ➤ Subscribe PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
00071 Netherlands ➤ Subscribe PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
C0003 France ➤ Subscribe PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
US Department of Justice
Teva
Covington
Chinese Patent Office
Accenture
Boehringer Ingelheim
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot